| scholarly article | Q13442814 |
| P50 | author | Jessica E Haberer | Q57891949 |
| Jared M Baeten | Q89443633 | ||
| P2093 | author name string | Albert Y. Liu | |
| Nirupama Sista | |||
| P2860 | cites work | Increased HIV incidence in men who have sex with men despite high levels of ART-induced viral suppression: analysis of an extensively documented epidemic | Q21133704 |
| Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men | Q24612082 | ||
| Prevention of HIV-1 infection with early antiretroviral therapy | Q24634688 | ||
| Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group | Q28239283 | ||
| Antiretroviral prophylaxis for HIV prevention in heterosexual men and women | Q28270788 | ||
| Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir | Q28472146 | ||
| Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco | Q28476730 | ||
| Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir Study, Thailand | Q28477258 | ||
| Preexposure prophylaxis for HIV infection among African women | Q29620077 | ||
| Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana | Q29620078 | ||
| Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial | Q33873955 | ||
| Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study | Q34081339 | ||
| Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples | Q35214337 | ||
| Antiretroviral prophylaxis: a defining moment in HIV control | Q35659658 | ||
| Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission | Q36353342 | ||
| Differences between clinical trial efficacy and real-world effectiveness | Q36656449 | ||
| Pre-exposure prophylaxis for HIV prevention: how to predict success | Q36839567 | ||
| Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. | Q37042094 | ||
| Periconception pre-exposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation | Q37172505 | ||
| What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples | Q37304108 | ||
| Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine | Q37365377 | ||
| HIV pre-exposure prophylaxis diffusion and implementation issues in nonclinical settings | Q38068650 | ||
| Primary care and public health partnerships for implementing pre-exposure prophylaxis. | Q38068660 | ||
| Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine | Q42274867 | ||
| Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection | Q43108142 | ||
| Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults | Q44109830 | ||
| Facilitators and barriers to medication adherence in an HIV prevention study among men who have sex with men in the iPrEx study in Chiang Mai, Thailand | Q44236500 | ||
| Serodiscordancy and HIV prevention in sub-Saharan Africa | Q45284575 | ||
| Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges | Q45412452 | ||
| Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission | Q46558677 | ||
| Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. | Q51157878 | ||
| Adherence, compliance, and HAART. | Q53966618 | ||
| Protecting the Next Generation — Eliminating Perinatal HIV-1 Infection | Q57953612 | ||
| From efficacy to impact: an advocate's agenda for HIV pre-exposure prophylaxis implementation | Q85739377 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prevention of HIV/AIDS | Q7242372 |
| P304 | page(s) | S122-9 | |
| P577 | publication date | 2013-07-01 | |
| P1433 | published in | Journal of Acquired Immune Deficiency Syndromes | Q6294722 |
| P1476 | title | Preexposure prophylaxis for HIV prevention: where have we been and where are we going? | |
| P478 | volume | 63 Suppl 2 |
| Q40251251 | "Life-Steps" for PrEP Adherence: Demonstration of a CBT-Based Intervention to Increase Adherence to Preexposure Prophylaxis (PrEP) Medication Among Sexual-Minority Men at High Risk for HIV Acquisition |
| Q36263599 | A Latent Class Analysis of Risk Factors for Acquiring HIV Among Men Who Have Sex with Men: Implications for Implementing Pre-Exposure Prophylaxis Programs |
| Q34077706 | A paradigm shift: focus on the HIV prevention continuum |
| Q35194068 | A scoping review and thematic analysis of social and behavioural research among HIV-serodiscordant couples in high-income settings |
| Q37460188 | AIDS: The final chapter? |
| Q38650563 | Acceptability of Daily Use of Free Oral Pre-exposure Prophylaxis (PrEP) Among Transgender Women Sex Workers in Shenyang, China |
| Q88690662 | An Empiric Risk Score to Guide PrEP Targeting Among MSM in Coastal Kenya |
| Q38660885 | An Evaluation of a Clinical Pre-Exposure Prophylaxis Education Intervention among Men Who Have Sex with Men. |
| Q30365108 | An action agenda for HIV and sex workers. |
| Q92481421 | Analysis of self-reported adverse reactions to efavirenz and drug interactions in a population with HIV in Mexico |
| Q34077715 | Antiretroviral chemoprophylaxis: state of evidence and the research agenda |
| Q47393141 | Applying network analysis to psychological comorbidity and health behavior: Depression, PTSD, and sexual risk in sexual minority men with trauma histories |
| Q33765795 | Biomedical prevention: state of the science |
| Q40566237 | Brief Report: PrEP Uptake, Adherence, and Discontinuation Among California YMSM Using Geosocial Networking Applications |
| Q35541521 | Clinical Treatment Options Infectious Diseases: Update on PrEP Implementation, Adherence, and Advances in Delivery |
| Q42203943 | Combination HIV prevention for female sex workers: what is the evidence? |
| Q38659668 | Combined interventions to reduce HIV incidence in KwaZulu-Natal: a modelling study |
| Q33798045 | Correlation between plasma, intracellular, and cervical tissue levels of raltegravir at steady-state dosing in healthy women |
| Q40335852 | Correlation of Adherence by Pill Count, Self-report, MEMS and Plasma Drug Levels to Treatment Response Among Women Receiving ARV Therapy for PMTCT in Kenya |
| Q35780443 | Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm |
| Q92715433 | Demographic characteristics associated with the use of HIV pre-exposure prophylaxis (PrEP) in an urban, community health center |
| Q59813153 | Early antiretroviral therapy and daily pre-exposure prophylaxis for HIV prevention among female sex workers in Cotonou, Benin: a prospective observational demonstration study |
| Q28658226 | Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco |
| Q90662882 | Elevated HIV Prevalence and Correlates of PrEP Use Among a Community Sample of Black Men Who Have Sex With Men |
| Q30365998 | Ending the global HIV/AIDS pandemic: the critical role of an HIV vaccine. |
| Q34531219 | Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity |
| Q49382513 | Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States |
| Q90392066 | Gender Identity and Sexual Orientation in Chinese Men Who Have Sex with Men: A Latent Class Analysis |
| Q90254973 | Generating CHARISMA: Development of an Intervention to Help Women Build Agency and Safety in Their Relationships While Using PrEP for HIV Prevention |
| Q33703135 | Global HIV epidemiology: A guide for strategies in prevention and care. |
| Q46119171 | HIV and adolescents: focus on young key populations |
| Q57207278 | HIV-1 Drug Resistance in Pre-exposure Prophylaxis Trials |
| Q91615082 | HIV-1 self-testing to improve the efficiency of pre-exposure prophylaxis delivery: a randomized trial in Kenya |
| Q30877918 | High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project |
| Q35108128 | Inclusion of trans women in pre-exposure prophylaxis trials: a review |
| Q40324021 | Levels of Intracellular Phosphorylated Tenofovir and Emtricitabine Correlate With Natural Substrate Concentrations in Peripheral Blood Mononuclear Cells of Persons Prescribed Daily Oral Truvada for HIV Pre-exposure Prophylaxis |
| Q34978897 | Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial |
| Q37618276 | M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures |
| Q35561488 | Male Partner Influence on Women's HIV Prevention Trial Participation and Use of Pre-exposure Prophylaxis: the Importance of "Understanding". |
| Q57173490 | Medical students reflect on the future of Pre-Exposure Prophylaxis use among adolescents and young adults |
| Q34606560 | Medication adherence among men who have sex with men at risk for HIV infection in the United States: implications for pre-exposure prophylaxis implementation |
| Q36148056 | Minimal Awareness and Stalled Uptake of Pre-Exposure Prophylaxis (PrEP) Among at Risk, HIV-Negative, Black Men Who Have Sex with Men |
| Q90709655 | Motives for choosing, switching and stopping daily or event-driven pre-exposure prophylaxis - a qualitative analysis |
| Q27318354 | Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission |
| Q42225882 | Non-human primate models of hormonal contraception and HIV. |
| Q27023352 | Oral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challenges |
| Q38853819 | Perceived Risk Among Human Immunodeficiency Virus Serodiscordant Couples in East Africa Taking Oral Pre-Exposure Prophylaxis |
| Q61946146 | Persistence on HIV preexposure prophylaxis medication over a 2-year period among a national sample of 7148 PrEP users, United States, 2015 to 2017 |
| Q30670919 | Phylogenetic Investigation of a Statewide HIV-1 Epidemic Reveals Ongoing and Active Transmission Networks Among Men Who Have Sex With Men. |
| Q36204808 | Planning ahead for implementation of long-acting HIV prevention: challenges and opportunities |
| Q46440280 | Potential Healthcare Insurance and Provider Barriers to Pre-Exposure Prophylaxis Utilization Among Young Men Who Have Sex with Men. |
| Q36003735 | Potential impact of multiple interventions on HIV incidence in a hyperendemic region in Western Kenya: a modelling study |
| Q37242825 | Potential impact of pre-exposure prophylaxis for female sex workers and men who have sex with men in Bangalore, India: a mathematical modelling study |
| Q43241737 | PrEP Implementation Science: State-of-the-Art and Research Agenda |
| Q61798882 | PrEP uptake preferences among men who have sex with men in China: results from a National Internet Survey |
| Q37639989 | Pre-Exposure Prophylaxis (PrEP) as an Additional Tool for HIV Prevention Among Men Who Have Sex With Men in Belgium: The Be-PrEP-ared Study Protocol |
| Q56913069 | Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa |
| Q35875719 | Pre-exposure prophylaxis in Southern Africa: feasible or not? |
| Q87419029 | Pre-exposure prophylaxis to intensify the fight against HIV |
| Q34061718 | Preparing for PrEP: perceptions and readiness of canadian physicians for the implementation of HIV pre-exposure prophylaxis |
| Q26828445 | Preventing HIV infection: pre-exposure and postexposure prophylaxis |
| Q57154336 | Qualitative Consumer Research on Acceptance of Long-acting PrEP Products among MSM and Medical Practitioners in the United States |
| Q47584347 | Recruitment of Underrepresented Minority Researchers into HIV Prevention Research: The HIV Prevention Trials Network Scholars Program |
| Q38233289 | Regulatory considerations for antiretroviral prophylaxis to prevent HIV acquisition. |
| Q41235922 | Repeat Use of Post-exposure Prophylaxis for HIV Among Nairobi-Based Female Sex Workers Following Sexual Exposure |
| Q35798274 | Repeated Vaginal SHIV Challenges in Macaques Receiving Oral or Topical Preexposure Prophylaxis Induce Virus-Specific T-Cell Responses |
| Q46503602 | Residual hormone levels in used contraceptive rings as a measurement of adherence to vaginal ring use. |
| Q35875710 | Rethinking HIV prevention to prepare for oral PrEP implementation for young African women |
| Q35473551 | Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis |
| Q36118829 | Sexual Behavior, Risk Compensation, and HIV Prevention Strategies Among Participants in the San Francisco PrEP Demonstration Project: A Qualitative Analysis of Counseling Notes |
| Q92119825 | Short- and Long-Term Pharmacologic Measures of HIV Pre-exposure Prophylaxis Use Among High-Risk Men Who Have Sex With Men in HPTN 067/ADAPT |
| Q30858811 | Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial |
| Q38742749 | Successful Implementation of HIV Preexposure Prophylaxis: Lessons Learned From Three Clinical Settings |
| Q35131207 | Tailored combination prevention packages and PrEP for young key populations |
| Q35575958 | Targeting pre-exposure prophylaxis among men who have sex with men in the United States and Peru: partnership types, contact rates, and sexual role |
| Q36443803 | Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women |
| Q59392817 | The Role of Social Relationships in PrEP Uptake and Use Among Transgender Women and Men Who Have Sex with Men |
| Q37212913 | The current status of the use of oral medication to prevent HIV transmission |
| Q34127809 | Towards an integrated framework for accelerating the end for the global HIV epidemic among young people |
| Q61443658 | Understanding women's motivations to participate in MTN-003/VOICE, a phase 2b HIV prevention trial with low adherence |
| Q37194802 | Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women |
| Q38649106 | Using Digital Technologies in Clinical HIV Research: Real-World Applications and Considerations for Future Work. |
| Q38638346 | Using surrogate vaccines to assess feasibility and acceptability of future HIV vaccine trials in men: a randomised trial in inner-city Johannesburg, South Africa |
| Q40708259 | When and why women might suspend PrEP use according to perceived seasons of risk: implications for PrEP-specific risk-reduction counselling |
| Q48101425 | Why I Quit Pre-Exposure Prophylaxis (PrEP)? A Mixed-Method Study Exploring Reasons for PrEP Discontinuation and Potential Re-initiation Among Gay and Bisexual Men. |
| Q28540042 | Women's experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa |
Search more.